Biocon founder Kiran Mazumdar-Shaw has finally shared her succession plan, putting an end to long-standing curiosity around who will lead the company next. She has confirmed that her niece, Claire Mazumdar, is being prepared to take over in the future, according to Fortune India.
Mazumdar-Shaw said she believes Claire is the right person to guide Biocon into its next phase. With no children of her own, she emphasised the importance of handing the company to someone she trusts. She added that Claire has already shown strong leadership skills and the ability to run a business.
The change in leadership will not happen overnight. Mazumdar-Shaw made it clear that she is not stepping down anytime soon. Instead, the transition will be gradual, allowing Claire to slowly take on more responsibility while ensuring stability within the company.
Claire Mazumdar is currently the founder and CEO of Bicara Therapeutics, a company that was incubated by Biocon. She has a strong academic background, with degrees from MIT and Stanford, including a PhD in cancer biology.
Her experience also includes working with global biotech firms. Bicara, which went public in 2024, has already built a solid market presence.
Mazumdar-Shaw also spoke about the wider family’s role in supporting the business. Claire’s brother, Eric Mazumdar, is an expert in artificial intelligence, while her husband, Thomas Roberts, is a well-known oncologist. Together, they bring a mix of scientific and technological expertise.
Alongside leadership changes, Biocon is reshaping its business. The company has combined its generics and biologics units, cut down debt, and simplified its structure. A major focus is on biosimilars, which already make up a large part of its revenue. Several products are in the pipeline.
Other key roles are also seeing changes. Shreehas Tambe is now leading Biocon Biologics, while Siddharth Mittal will take charge of Syngene International from July.
Looking ahead, Mazumdar-Shaw said Biocon will continue to invest in advanced biotechnology and artificial intelligence. The aim is to develop new drugs and strengthen research capabilities, ensuring long-term growth.